AI Science Tracker
EN

Zhejiang Chinese Medical University

1 discovery from 2026

Discoveries

Learned three-gene score shows retrospective survival association in hepatitis-associated liver cancer

Source check: Source checked. Not independent scientific confirmation.

Finding: CoxBoost combined with elastic-net regression formed a three-gene survival score for hepatitis-B-associated hepatocellular carcinoma. The paper reports survival separation in sixty TCGA and fifty-seven comparison-cohort samples. Both cohorts informed algorithm selection, limiting independent validation. The finding is a retrospective clinical association, without demonstrated treatment benefit or causal immune regulation.

Technology: CoxBoost and elastic-net regression for a three-gene survival-risk score

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Boosted Cox learning and elastic-net fitting combined the three expression features into a risk score linked to measured patient survival. Univariate gene screening, generic enrichment and AI-agent drug suggestions alone are not the admitted result.
Test and result
The source selected sixty TCGA and fifty-seven HCCDB18 samples with clinical information. It compared 101 combinations of ten algorithms, using C-indices in both cohorts to choose CoxBoost plus elastic net with alpha 0.4. The learned score combined PARP1, KPNB1 and FARP2. Kaplan–Meier and time-dependent ROC analyses reported associations with observed overall survival in both cohorts.
Limitation / still unknown
The comparison cohort influenced model selection and is not an untouched external test. Small selected cohorts, incompletely reconstructed eligibility and outcome-informed comparisons limit generalization. Exact figure-level performance values were not independently transcribed. This record does not adopt predicted drug synergy, therapeutic reversal, causal immune effects or experimental biological claims.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://link.springer.com/article/10.1007/s12672-026-05487-y

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 21 Nov 2026. Review scope: Read primary clinical cohort acquisition, ten-algorithm/101-combination selection, CoxBoost/elastic-net evaluation Methods and survival-model Results. Operational biological procedures and drug claims were not processed or adjudicated. Figure-level numerical performance and supplements were not independently reconstructed. Exact original article front DOI/title and fresh PubMed primary relationship metadata checked..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 1/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.